Aktienanalyse zu CDT Equity Inc (CDT)CDTCDT Equity Inc

CDT Equity Inc., formerly Conduit Pharmaceuticals, Inc. is a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Through advanced co-crystallization and solidform technologies developed at its Cambridge facility, it is engaged in improving drug properties and has helped in extending the patent life of certain drugs by up to 20 years. Its pipeline includes candidates targeting inflammatory and autoimmune disorders, as well as idiopathic male infertility, dermatology and animal health. It applies proprietary algorithms utilizing AI-powered disease mapping to identify novel repurposing opportunities against a database of over 800 disease signatures. In addition, the Company has initiated pre-clinical in-vitro models to explore new indications, guided by AI-insights without human intervention. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Conduit Pharmaceuticals Inc (CDT) is not a good buy right now due to its current price of $0.13, which has dropped 100% year-to-date and 93.5% over the last 20 days. The RSI is extremely low at 3.297, indicating oversold conditions, but this is coupled with a negative sentiment and significant financial losses, including a net income of -24,325,000 USD in Q4 2025. The main risk is the company's ongoing financial instability, highlighted by a current ratio of only 0.13, indicating poor liquidity and potential solvency issues.